05/14/2026
The Supreme Court's decision to maintain telehealth access to mifepristone preserves a critical pathway to care, including for patients living in states with abortion bans for whom telehealth can be a critical access point. It does not, however, erase the broader threat facing medication abortion care.
Telehealth has been a critical pathway to care, particularly for people in rural areas and those navigating travel to clinics, time off work, or child care. The evidence has long shown that mifepristone is safe, effective, and an essential part of reproductive and miscarriage care.
This case continues, and Trump and his allies will also continue their attacks. The fact that patients’ ability to access this medication can hinge on week-to-week court decisions and the whims of anti-abortion politicians underscores how relentless the attack on reproductive freedom has become. States committed to defending reproductive freedom must act now to defend against future attacks by shielding providers from out-of-state prosecution for providing abortion care, safeguarding patient data from surveillance, and ensuring that people can afford care in the face of escalating attacks.
Louisiana had sued the FDA in a bid to curtail the regulatory agency’s rules on prescribing mifepristone remotely